Moderna: The third dose of vaccine enhances Delta's neutralization ability by 42 times, and 15 projects enter the clinic

Today, Moderna released its financial report for the second quarter of 2021

The data released in the second quarter financial report showed that the mRNA-1273 vaccine is still more than 90% effective in preventing symptomatic COVID-19 6 months after vaccination

Phase 3 clinical trial data show that vaccine efficacy is maintained within 6 months

Moderna announced the latest follow-up results of the mRNA-1273 vaccine in a phase 3 clinical trial called COVE

▲The protective efficacy of mRNA-1273 vaccine in different time periods after vaccination (picture source: reference [3])

The third dose of booster vaccine significantly improves the ability to neutralize new crown variants

At present, a variety of new crown variants are popular all over the world, and they all have different degrees of immune escape ability

Therefore, the company is already conducting phase 2 clinical trials to test the effectiveness of the third dose of the booster vaccine

The test results showed that 6 months after the second dose of vaccine, the level of neutralizing antibodies against wild-type new coronavirus remained at a high level, however, against Beta (B.

▲The third dose of enhanced vaccine significantly improves the ability to neutralize the new crown variants (picture source: reference [3])

The company believes that current clinical data supports the use of a dose of 50 μg of mRNA-1273 as a booster vaccine.

15 R&D projects entered the clinical development stage

In addition to the new crown vaccine, Moderna is also working on developing other applications of mRNA technology

In terms of cancer vaccine development, the company has cooperated with Merck & Co.

The mRNA vaccine expressing the KRAS mutant is also used as a single agent or in combination with Keytruda in phase 1 clinical trials, and undergoes safety and tolerability assessments

▲Moderna's R&D pipeline (picture source: reference [3])

Note: The original text has been deleted

Reference materials:

[1] KRAS vaccine (mRNA-5671).

[2] Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates.

[3] Business Updates Second Quarter 2021 Financial Results.